Global Lung Disease Therapeutics Market Growth (Status and Outlook) 2026-2032

May 2026 | 108 pages | ID: G19E43963317EN
LP Information

Abstracts

The global Lung Disease Therapeutics market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LPI (LP Information)' newest research report, the “Lung Disease Therapeutics Industry Forecast” looks at past sales and reviews total world Lung Disease Therapeutics sales in 2025, providing a comprehensive analysis by region and market sector of projected Lung Disease Therapeutics sales for 2026 through 2032. With Lung Disease Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Lung Disease Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Lung Disease Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Lung Disease Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Lung Disease Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Lung Disease Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Lung Disease Therapeutics.

This report presents a comprehensive overview, market shares, and growth opportunities of Lung Disease Therapeutics market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Lung Cancer
• Other Lung Diseases

Segmentation by Application:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• GSK
• AstraZeneca
• Boehringer Ingelheim
• Novartis
• Mylan
• Vertex Pharmaceuticals
• F. Hoffman La Roche
• Teva Pharmaceuticals
• Cipla
• Fibrogen
• Liminal Biosciences
• PharmAkea Therapeutics
• IQVIA

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Lung Disease Therapeutics Market Size (2021-2032)
  2.1.2 Lung Disease Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032)
  2.1.3 World Current & Future Analysis for Lung Disease Therapeutics by Country/Region (2021, 2025 & 2032)
2.2 Lung Disease Therapeutics Segment by Type
  2.2.1 Asthma
  2.2.2 Chronic Obstructive Pulmonary Disease (COPD)
  2.2.3 Lung Cancer
  2.2.4 Other Lung Diseases
  2.2.5 Lung Disease Therapeutics Market Size by Type
    2.2.5.1 Lung Disease Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032)
    2.2.5.2 Global Lung Disease Therapeutics Market Size Market Share by Type (2021-2026)
2.3 Lung Disease Therapeutics Segment by Application
  2.3.1 Hospital Pharmacies
  2.3.2 Retail Pharmacies
  2.3.3 Online Pharmacies
  2.3.4 Lung Disease Therapeutics Market Size by Application
    2.3.4.1 Lung Disease Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032)
    2.3.4.2 Global Lung Disease Therapeutics Market Size Market Share by Application (2021-2026)

3 LUNG DISEASE THERAPEUTICS MARKET SIZE BY PLAYER

3.1 Lung Disease Therapeutics Market Size Market Share by Player
  3.1.1 Global Lung Disease Therapeutics Revenue by Player (2021-2026)
  3.1.2 Global Lung Disease Therapeutics Revenue Market Share by Player (2021-2026)
3.2 Global Lung Disease Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 LUNG DISEASE THERAPEUTICS BY REGION

4.1 Lung Disease Therapeutics Market Size by Region (2021-2026)
4.2 Global Lung Disease Therapeutics Annual Revenue by Country/Region (2021-2026)
4.3 Americas Lung Disease Therapeutics Market Size Growth (2021-2026)
4.4 APAC Lung Disease Therapeutics Market Size Growth (2021-2026)
4.5 Europe Lung Disease Therapeutics Market Size Growth (2021-2026)
4.6 Middle East & Africa Lung Disease Therapeutics Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas Lung Disease Therapeutics Market Size by Country (2021-2026)
5.2 Americas Lung Disease Therapeutics Market Size by Type (2021-2026)
5.3 Americas Lung Disease Therapeutics Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Lung Disease Therapeutics Market Size by Region (2021-2026)
6.2 APAC Lung Disease Therapeutics Market Size by Type (2021-2026)
6.3 APAC Lung Disease Therapeutics Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Lung Disease Therapeutics Market Size by Country (2021-2026)
7.2 Europe Lung Disease Therapeutics Market Size by Type (2021-2026)
7.3 Europe Lung Disease Therapeutics Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Lung Disease Therapeutics by Region (2021-2026)
8.2 Middle East & Africa Lung Disease Therapeutics Market Size by Type (2021-2026)
8.3 Middle East & Africa Lung Disease Therapeutics Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL LUNG DISEASE THERAPEUTICS MARKET FORECAST

10.1 Global Lung Disease Therapeutics Forecast by Region (2027-2032)
  10.1.1 Global Lung Disease Therapeutics Forecast by Region (2027-2032)
  10.1.2 Americas Lung Disease Therapeutics Forecast
  10.1.3 APAC Lung Disease Therapeutics Forecast
  10.1.4 Europe Lung Disease Therapeutics Forecast
  10.1.5 Middle East & Africa Lung Disease Therapeutics Forecast
10.2 Americas Lung Disease Therapeutics Forecast by Country (2027-2032)
  10.2.1 United States Market Lung Disease Therapeutics Forecast
  10.2.2 Canada Market Lung Disease Therapeutics Forecast
  10.2.3 Mexico Market Lung Disease Therapeutics Forecast
  10.2.4 Brazil Market Lung Disease Therapeutics Forecast
10.3 APAC Lung Disease Therapeutics Forecast by Region (2027-2032)
  10.3.1 China Lung Disease Therapeutics Market Forecast
  10.3.2 Japan Market Lung Disease Therapeutics Forecast
  10.3.3 Korea Market Lung Disease Therapeutics Forecast
  10.3.4 Southeast Asia Market Lung Disease Therapeutics Forecast
  10.3.5 India Market Lung Disease Therapeutics Forecast
  10.3.6 Australia Market Lung Disease Therapeutics Forecast
10.4 Europe Lung Disease Therapeutics Forecast by Country (2027-2032)
  10.4.1 Germany Market Lung Disease Therapeutics Forecast
  10.4.2 France Market Lung Disease Therapeutics Forecast
  10.4.3 UK Market Lung Disease Therapeutics Forecast
  10.4.4 Italy Market Lung Disease Therapeutics Forecast
  10.4.5 Russia Market Lung Disease Therapeutics Forecast
10.5 Middle East & Africa Lung Disease Therapeutics Forecast by Region (2027-2032)
  10.5.1 Egypt Market Lung Disease Therapeutics Forecast
  10.5.2 South Africa Market Lung Disease Therapeutics Forecast
  10.5.3 Israel Market Lung Disease Therapeutics Forecast
  10.5.4 Turkey Market Lung Disease Therapeutics Forecast
10.6 Global Lung Disease Therapeutics Forecast by Type (2027-2032)
10.7 Global Lung Disease Therapeutics Forecast by Application (2027-2032)
  10.7.1 GCC Countries Market Lung Disease Therapeutics Forecast

11 KEY PLAYERS ANALYSIS

11.1 GSK
  11.1.1 GSK Company Information
  11.1.2 GSK Lung Disease Therapeutics Product Offered
  11.1.3 GSK Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
  11.1.4 GSK Main Business Overview
  11.1.5 GSK Latest Developments
11.2 AstraZeneca
  11.2.1 AstraZeneca Company Information
  11.2.2 AstraZeneca Lung Disease Therapeutics Product Offered
  11.2.3 AstraZeneca Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
  11.2.4 AstraZeneca Main Business Overview
  11.2.5 AstraZeneca Latest Developments
11.3 Boehringer Ingelheim
  11.3.1 Boehringer Ingelheim Company Information
  11.3.2 Boehringer Ingelheim Lung Disease Therapeutics Product Offered
  11.3.3 Boehringer Ingelheim Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
  11.3.4 Boehringer Ingelheim Main Business Overview
  11.3.5 Boehringer Ingelheim Latest Developments
11.4 Novartis
  11.4.1 Novartis Company Information
  11.4.2 Novartis Lung Disease Therapeutics Product Offered
  11.4.3 Novartis Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
  11.4.4 Novartis Main Business Overview
  11.4.5 Novartis Latest Developments
11.5 Mylan
  11.5.1 Mylan Company Information
  11.5.2 Mylan Lung Disease Therapeutics Product Offered
  11.5.3 Mylan Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
  11.5.4 Mylan Main Business Overview
  11.5.5 Mylan Latest Developments
11.6 Vertex Pharmaceuticals
  11.6.1 Vertex Pharmaceuticals Company Information
  11.6.2 Vertex Pharmaceuticals Lung Disease Therapeutics Product Offered
  11.6.3 Vertex Pharmaceuticals Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
  11.6.4 Vertex Pharmaceuticals Main Business Overview
  11.6.5 Vertex Pharmaceuticals Latest Developments
11.7 F. Hoffman La Roche
  11.7.1 F. Hoffman La Roche Company Information
  11.7.2 F. Hoffman La Roche Lung Disease Therapeutics Product Offered
  11.7.3 F. Hoffman La Roche Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
  11.7.4 F. Hoffman La Roche Main Business Overview
  11.7.5 F. Hoffman La Roche Latest Developments
11.8 Teva Pharmaceuticals
  11.8.1 Teva Pharmaceuticals Company Information
  11.8.2 Teva Pharmaceuticals Lung Disease Therapeutics Product Offered
  11.8.3 Teva Pharmaceuticals Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
  11.8.4 Teva Pharmaceuticals Main Business Overview
  11.8.5 Teva Pharmaceuticals Latest Developments
11.9 Cipla
  11.9.1 Cipla Company Information
  11.9.2 Cipla Lung Disease Therapeutics Product Offered
  11.9.3 Cipla Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
  11.9.4 Cipla Main Business Overview
  11.9.5 Cipla Latest Developments
11.10 Fibrogen
  11.10.1 Fibrogen Company Information
  11.10.2 Fibrogen Lung Disease Therapeutics Product Offered
  11.10.3 Fibrogen Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
  11.10.4 Fibrogen Main Business Overview
  11.10.5 Fibrogen Latest Developments
11.11 Liminal Biosciences
  11.11.1 Liminal Biosciences Company Information
  11.11.2 Liminal Biosciences Lung Disease Therapeutics Product Offered
  11.11.3 Liminal Biosciences Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
  11.11.4 Liminal Biosciences Main Business Overview
  11.11.5 Liminal Biosciences Latest Developments
11.12 PharmAkea Therapeutics
  11.12.1 PharmAkea Therapeutics Company Information
  11.12.2 PharmAkea Therapeutics Lung Disease Therapeutics Product Offered
  11.12.3 PharmAkea Therapeutics Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
  11.12.4 PharmAkea Therapeutics Main Business Overview
  11.12.5 PharmAkea Therapeutics Latest Developments
11.13 IQVIA
  11.13.1 IQVIA Company Information
  11.13.2 IQVIA Lung Disease Therapeutics Product Offered
  11.13.3 IQVIA Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
  11.13.4 IQVIA Main Business Overview
  11.13.5 IQVIA Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Lung Disease Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Lung Disease Therapeutics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Asthma
Table 4. Major Players of Chronic Obstructive Pulmonary Disease (COPD)
Table 5. Major Players of Lung Cancer
Table 6. Major Players of Other Lung Diseases
Table 7. Lung Disease Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 8. Global Lung Disease Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 9. Global Lung Disease Therapeutics Market Size Market Share by Type (2021-2026)
Table 10. Lung Disease Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 11. Global Lung Disease Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 12. Global Lung Disease Therapeutics Market Size Market Share by Application (2021-2026)
Table 13. Global Lung Disease Therapeutics Revenue by Player (2021-2026) & ($ millions)
Table 14. Global Lung Disease Therapeutics Revenue Market Share by Player (2021-2026)
Table 15. Lung Disease Therapeutics Key Players Head office and Products Offered
Table 16. Lung Disease Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Lung Disease Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 20. Global Lung Disease Therapeutics Market Size Market Share by Region (2021-2026)
Table 21. Global Lung Disease Therapeutics Revenue by Country/Region (2021-2026) & ($ millions)
Table 22. Global Lung Disease Therapeutics Revenue Market Share by Country/Region (2021-2026)
Table 23. Americas Lung Disease Therapeutics Market Size by Country (2021-2026) & ($ millions)
Table 24. Americas Lung Disease Therapeutics Market Size Market Share by Country (2021-2026)
Table 25. Americas Lung Disease Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 26. Americas Lung Disease Therapeutics Market Size Market Share by Type (2021-2026)
Table 27. Americas Lung Disease Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 28. Americas Lung Disease Therapeutics Market Size Market Share by Application (2021-2026)
Table 29. APAC Lung Disease Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 30. APAC Lung Disease Therapeutics Market Size Market Share by Region (2021-2026)
Table 31. APAC Lung Disease Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 32. APAC Lung Disease Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 33. Europe Lung Disease Therapeutics Market Size by Country (2021-2026) & ($ millions)
Table 34. Europe Lung Disease Therapeutics Market Size Market Share by Country (2021-2026)
Table 35. Europe Lung Disease Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 36. Europe Lung Disease Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 37. Middle East & Africa Lung Disease Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 38. Middle East & Africa Lung Disease Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 39. Middle East & Africa Lung Disease Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Lung Disease Therapeutics
Table 41. Key Market Challenges & Risks of Lung Disease Therapeutics
Table 42. Key Industry Trends of Lung Disease Therapeutics
Table 43. Global Lung Disease Therapeutics Market Size Forecast by Region (2027-2032) & ($ millions)
Table 44. Global Lung Disease Therapeutics Market Size Market Share Forecast by Region (2027-2032)
Table 45. Global Lung Disease Therapeutics Market Size Forecast by Type (2027-2032) & ($ millions)
Table 46. Global Lung Disease Therapeutics Market Size Forecast by Application (2027-2032) & ($ millions)
Table 47. GSK Details, Company Type, Lung Disease Therapeutics Area Served and Its Competitors
Table 48. GSK Lung Disease Therapeutics Product Offered
Table 49. GSK Lung Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 50. GSK Main Business
Table 51. GSK Latest Developments
Table 52. AstraZeneca Details, Company Type, Lung Disease Therapeutics Area Served and Its Competitors
Table 53. AstraZeneca Lung Disease Therapeutics Product Offered
Table 54. AstraZeneca Lung Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 55. AstraZeneca Main Business
Table 56. AstraZeneca Latest Developments
Table 57. Boehringer Ingelheim Details, Company Type, Lung Disease Therapeutics Area Served and Its Competitors
Table 58. Boehringer Ingelheim Lung Disease Therapeutics Product Offered
Table 59. Boehringer Ingelheim Lung Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. Boehringer Ingelheim Main Business
Table 61. Boehringer Ingelheim Latest Developments
Table 62. Novartis Details, Company Type, Lung Disease Therapeutics Area Served and Its Competitors
Table 63. Novartis Lung Disease Therapeutics Product Offered
Table 64. Novartis Lung Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. Novartis Main Business
Table 66. Novartis Latest Developments
Table 67. Mylan Details, Company Type, Lung Disease Therapeutics Area Served and Its Competitors
Table 68. Mylan Lung Disease Therapeutics Product Offered
Table 69. Mylan Lung Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Mylan Main Business
Table 71. Mylan Latest Developments
Table 72. Vertex Pharmaceuticals Details, Company Type, Lung Disease Therapeutics Area Served and Its Competitors
Table 73. Vertex Pharmaceuticals Lung Disease Therapeutics Product Offered
Table 74. Vertex Pharmaceuticals Lung Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Vertex Pharmaceuticals Main Business
Table 76. Vertex Pharmaceuticals Latest Developments
Table 77. F. Hoffman La Roche Details, Company Type, Lung Disease Therapeutics Area Served and Its Competitors
Table 78. F. Hoffman La Roche Lung Disease Therapeutics Product Offered
Table 79. F. Hoffman La Roche Lung Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. F. Hoffman La Roche Main Business
Table 81. F. Hoffman La Roche Latest Developments
Table 82. Teva Pharmaceuticals Details, Company Type, Lung Disease Therapeutics Area Served and Its Competitors
Table 83. Teva Pharmaceuticals Lung Disease Therapeutics Product Offered
Table 84. Teva Pharmaceuticals Lung Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Teva Pharmaceuticals Main Business
Table 86. Teva Pharmaceuticals Latest Developments
Table 87. Cipla Details, Company Type, Lung Disease Therapeutics Area Served and Its Competitors
Table 88. Cipla Lung Disease Therapeutics Product Offered
Table 89. Cipla Lung Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. Cipla Main Business
Table 91. Cipla Latest Developments
Table 92. Fibrogen Details, Company Type, Lung Disease Therapeutics Area Served and Its Competitors
Table 93. Fibrogen Lung Disease Therapeutics Product Offered
Table 94. Fibrogen Lung Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Fibrogen Main Business
Table 96. Fibrogen Latest Developments
Table 97. Liminal Biosciences Details, Company Type, Lung Disease Therapeutics Area Served and Its Competitors
Table 98. Liminal Biosciences Lung Disease Therapeutics Product Offered
Table 99. Liminal Biosciences Lung Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. Liminal Biosciences Main Business
Table 101. Liminal Biosciences Latest Developments
Table 102. PharmAkea Therapeutics Details, Company Type, Lung Disease Therapeutics Area Served and Its Competitors
Table 103. PharmAkea Therapeutics Lung Disease Therapeutics Product Offered
Table 104. PharmAkea Therapeutics Lung Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 105. PharmAkea Therapeutics Main Business
Table 106. PharmAkea Therapeutics Latest Developments
Table 107. IQVIA Details, Company Type, Lung Disease Therapeutics Area Served and Its Competitors
Table 108. IQVIA Lung Disease Therapeutics Product Offered
Table 109. IQVIA Lung Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 110. IQVIA Main Business
Table 111. IQVIA Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Lung Disease Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Lung Disease Therapeutics Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Lung Disease Therapeutics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Lung Disease Therapeutics Sales Market Share by Country/Region (2025)
Figure 8. Lung Disease Therapeutics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Lung Disease Therapeutics Market Size Market Share by Type in 2025
Figure 10. Lung Disease Therapeutics in Hospital Pharmacies
Figure 11. Global Lung Disease Therapeutics Market: Hospital Pharmacies (2021-2026) & ($ millions)
Figure 12. Lung Disease Therapeutics in Retail Pharmacies
Figure 13. Global Lung Disease Therapeutics Market: Retail Pharmacies (2021-2026) & ($ millions)
Figure 14. Lung Disease Therapeutics in Online Pharmacies
Figure 15. Global Lung Disease Therapeutics Market: Online Pharmacies (2021-2026) & ($ millions)
Figure 16. Global Lung Disease Therapeutics Market Size Market Share by Application in 2025
Figure 17. Global Lung Disease Therapeutics Revenue Market Share by Player in 2025
Figure 18. Global Lung Disease Therapeutics Market Size Market Share by Region (2021-2026)
Figure 19. Americas Lung Disease Therapeutics Market Size 2021-2026 ($ millions)
Figure 20. APAC Lung Disease Therapeutics Market Size 2021-2026 ($ millions)
Figure 21. Europe Lung Disease Therapeutics Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Lung Disease Therapeutics Market Size 2021-2026 ($ millions)
Figure 23. Americas Lung Disease Therapeutics Value Market Share by Country in 2025
Figure 24. United States Lung Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Lung Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Lung Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Lung Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Lung Disease Therapeutics Market Size Market Share by Region in 2025
Figure 29. APAC Lung Disease Therapeutics Market Size Market Share by Type (2021-2026)
Figure 30. APAC Lung Disease Therapeutics Market Size Market Share by Application (2021-2026)
Figure 31. China Lung Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Lung Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Lung Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Lung Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 35. India Lung Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Lung Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Lung Disease Therapeutics Market Size Market Share by Country in 2025
Figure 38. Europe Lung Disease Therapeutics Market Size Market Share by Type (2021-2026)
Figure 39. Europe Lung Disease Therapeutics Market Size Market Share by Application (2021-2026)
Figure 40. Germany Lung Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 41. France Lung Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Lung Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Lung Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Lung Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Lung Disease Therapeutics Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Lung Disease Therapeutics Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Lung Disease Therapeutics Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Lung Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Lung Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Lung Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Lung Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Lung Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 54. APAC Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 55. Europe Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 57. United States Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 58. Canada Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 59. Mexico Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 60. Brazil Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 61. China Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 62. Japan Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 63. Korea Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 65. India Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 66. Australia Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 67. Germany Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 68. France Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 69. UK Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 70. Italy Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 71. Russia Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 72. Egypt Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 73. South Africa Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 74. Israel Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 75. Turkey Lung Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 76. Global Lung Disease Therapeutics Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Lung Disease Therapeutics Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Lung Disease Therapeutics Market Size 2027-2032 ($ millions)